$ cat ./records/gates-foundation-invests-55-million-in-biontech-for-mrna-hiv-and--2019.txt
Gates Foundation Invests $55 Million in BioNTech for mRNA HIV and Tuberculosis Vaccines
[RECORD.TXT] · cat --full
The Bill & Melinda Gates Foundation announced a $55 million equity investment in BioNTech SE — acquiring 3,038,674 ordinary shares — as part of a collaboration to develop mRNA-based preclinical vaccine and immunotherapy candidates against HIV and tuberculosis. The collaboration was structured to reach up to $100 million through follow-on grant funding. The investment predated BioNTech's COVID-19 vaccine work by more than a year and was entirely directed at two diseases that had long resisted conventional vaccine approaches. It is among the Gates Foundation's most consequential early bets on the mRNA platform.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
African Union Centre for Ticks and Tick-Borne Diseases Upgraded to Produce 2 Million ECF Vaccine Doses
Next →
Melinda Gates Consults Divorce Attorneys Following Epstein Coverage
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.